إعلان
إعلان
KLRS
Kalaris Therapeutics, Inc. Common Stock
9.82
USDبرعاية
+1.56
+18.95%
٠٩ يناير, ١٥:٥٨ UTC -5
مغلق
بعد الإغلاق
9.99
+0.17
+1.68%
تقارير أرباح KLRS
النسبة الإيجابية المفاجئة
KLRS تفوق 10 من 19 آخر التقديرات.
53%
التقرير التالي
بيانات التقرير القادم
٠٥ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.54
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/-15.63%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/--
Kalaris Therapeutics, Inc. Common Stock earnings per share and revenue
On ١٢ نوفمبر ٢٠٢٥, KLRS reported earnings of -0.64 USD per share (EPS) for Q3 25, beating the estimate of -0.66 USD, resulting in a 3.89% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.17% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 المحللين forecast an EPS of -0.54 USD, with revenue projected to reach -- USD, implying an نقصان of -15.63% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
What were Kalaris Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Kalaris Therapeutics, Inc. Common Stock reported EPS of -$0.64, beating estimates by 3.89%, and revenue of $0.00, 0% as expectations.
How did the market react to Kalaris Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -2.17%, changed from $5.07 before the earnings release to $4.96 the day after.
When is Kalaris Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for ٠٥ مارس ٢٠٢٦.
What are the forecasts for Kalaris Therapeutics, Inc. Common Stock's next earnings report?
Based on 8
المحللين, Kalaris Therapeutics, Inc. Common Stock is expected to report EPS of -$0.54 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان